AI-Driven Early Detection of Skin Cancer

NCT ID: NCT07144306

Last Updated: 2025-09-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-10-01

Study Completion Date

2026-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the feasibility and accuracy of an AI-powered mobile platform (NuvanaDx) for early detection of skin cancer, including melanoma, using smartphone-based imaging. The platform is designed to improve access to early diagnosis, reduce waiting times, and support triage into appropriate care pathways.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will collect retrospective and prospective anonymized skin lesion images and metadata to validate the AI algorithm against dermatology-confirmed diagnoses. The aim is to determine sensitivity, specificity, and predictive value of the AI tool across diverse populations and skin tones. The study will also assess user experience, accessibility, and integration into clinical care pathways.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Skin Cancer Melanoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

ECOLOGIC_OR_COMMUNITY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants with suspicious skin lesions undergoing AI-based image analysis and dermatologist confi

Smartphone-based AI skin lesion analysis (NuvanaDx platform).

Intervention Type DIAGNOSTIC_TEST

Smartphone-based AI skin lesion analysis (NuvanaDx platform).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Smartphone-based AI skin lesion analysis (NuvanaDx platform).

Smartphone-based AI skin lesion analysis (NuvanaDx platform).

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Adults (≥18 years) presenting with skin lesions suspicious for malignancy.

Ability to provide informed consent.

Exclusion Criteria

Inability to provide informed consent.

Poor-quality images unsuitable for AI analysis.
Minimum Eligible Age

18 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute for Health Research, United Kingdom

OTHER_GOV

Sponsor Role collaborator

Nuvana Healthcare LTD

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Aryan Chaudhary,

Role: STUDY_CHAIR

Scientific Advisor / Co-Founder, Nuvana Healthcare

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Nuvana Healthcare Ltd

London, , United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sushma Saxena, Director, Nuvana Healthcare Ltd

Role: CONTACT

+44 7481986525

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sushma Saxena, B.Tech, Msci

Role: primary

+44 7481986525

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

359904

Identifier Type: OTHER

Identifier Source: secondary_id

70148

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

AI Determine Malignancy of GGO on Chest CT
NCT06282068 ENROLLING_BY_INVITATION
Bioinformation Therapy for Lung Cancer
NCT03239171 COMPLETED PHASE2/PHASE3